周日报道，主角和武田提供了32周验证数据：Rusfertide显着减少静脉切开术，改善Vera红细胞增多症的症状

2025-06-02 15:42

Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint
All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes
No serious adverse events considered related to rusfertide were reported
Rusfertide has received Orphan Drug designation and Fast Track designation from the U.S. FDA